| Time Trends in Causes of Death in People With HIV : Insights From the Swiss HIV Cohort Study | Clinical infectious diseases |  | | 2024 | 19 | 184 |
|
| Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells | Nature medicine | | | 2024 | 17 | 37 |
|
| Singularités du Covid-19 chez les personnes immunosupprimées | Revue médicale suisse | | | 2024 | 20 | 56 |
|
| Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocol | BMC infectious diseases | | | 2024 | 137 | 526 |
|
| External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older | HIV medicine | | | 2023 | 105 | 98 |
|
| The international Unity study for antivirals against mpox is a blueprint for future epidemics | Nature medicine |  | | 2023 | 150 | 0 |
|
| Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants | Frontiers in microbiology | | | 2022 | 267 | 95 |
|
| Immunocompromised patients have been neglected in COVID-19 trials: a call for action | Clinical microbiology and infection | | | 2022 | 83 | 139 |
|
| A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab | Lancet. Infectious diseases | | | 2022 | 128 | 253 |
|
